Drug intelligence / Profile preview

Xiaoyan Tang

Development stage: Preclinical
Lead developer: Tianjin Science and Technology Planning Project
Administration: Oral

Overview

Xiaoyan Tang is a traditional Chinese medicine (TCM) formulation investigated as a therapeutic intervention, particularly in combination with apatinib mesylate, for advanced gastric cancer and advanced non-squamous, non-small cell lung cancer. Specific details regarding its exact composition and comprehensive mechanism of action are not publicly available through general searches, but as a 'Tang' (decoction), it is typically a multi-ingredient herbal preparation.

Beyond the preview

Go deeper on Xiaoyan Tang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaoyan Tang.

Explore the full profile